Dergiler / European Journal of Therapeutics / 2020 / Cilt: 26 - Sayı: 3

Herbal Drug BNO 1016 Versus Fluticasone Propionate Nasal Spray in the Treatment of Chronic Rhinosinusitis without Nasal Polyps: A Preliminary Report

Sayfa
192–201
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We evaluated the nasal total symptom score (TSS),individual scores for each symptom (nasal congestion/obstruction, rhinorrhea/postnasal discharge, facial pain with the sense ofpressure, headache, loss of the sense of smell), total endoscopic score (TES), and individual endoscopic signs (edema of the nasalmucosa, nasal secretion, and nasal crusting), before and after the therapy.Results: TSS was lower on Day 7 (p=0.008), Day 14 (p=0.004), Day 21 (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Current evidence supports the use of herbal drugs in the reduction of symptoms of acute (ARS) and chronic rhinosinusitis (CRS).
📊
Temel Bulgular & Veri:This studywas designed to compare the safety and efficacy of plant medication BNO 1016 and fluticasone propionate nasal spray (FPNS) fortreating CRS without nasal polyps (CRSsNP).Methods: Forty subjects with CRSsNP were randomly divided into two treatment groups that comprised 20 patients each.
💡
Sonuç & Katkı:We evaluated the nasal total symptom score (TSS),individual scores for each symptom (nasal congestion/obstruction, rhinorrhea/postnasal discharge, facial pain with the sense ofpressure, headache, loss of the sense of smell), total endoscopic score (TES), and individual endoscopic signs (edema of the nasalmucosa, nasal secretion, and nasal crusting), before and after the therapy.Results: TSS was lower on Day 7 (p=0.008), Day 14 (p=0.004), Day 21 (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Current evidence supports the use of herbal drugs in the reduction of symptoms of acute (ARS) and chronic rhinosinusitis (CRS). Intranasal corticosteroids are the first line treatment option for treating CRS with or without nasal polyps. This studywas designed to compare the safety and efficacy of plant medication BNO 1016 and fluticasone propionate nasal spray (FPNS) fortreating CRS without nasal polyps (CRSsNP).Methods: Forty subjects with CRSsNP were randomly divided into two treatment groups that comprised 20 patients each. Thepatients from Group 1 were treated with herbal drug BNO 1016, tablets of 160 mg, 3×1/d per os, for 28 d. The patients from Group2 used FPNS 200 μg once daily, 2 puffs in each nostril in the morning for 28 d. We evaluated the nasal total symptom score (TSS),individual scores for each symptom (nasal congestion/obstruction, rhinorrhea/postnasal discharge, facial pain with the sense ofpressure, headache, loss of the sense of smell), total endoscopic score (TES), and individual endoscopic signs (edema of the nasalmucosa, nasal secretion, and nasal crusting), before and after the therapy.Results: TSS was lower on Day 7 (p=0.008), Day 14 (p=0.004), Day 21 (p

🔖

Bu Makaleye Atıf Yap

PERİC, A., GACESA, D., ALEKSIC, A., KOPACHEVA-BARSOVA, G., PERİC, A. V. (2022). Herbal Drug BNO 1016 Versus Fluticasone Propionate Nasal Spray in the Treatment of Chronic Rhinosinusitis without Nasal Polyps: A Preliminary Report. European Journal of Therapeutics, Cilt: 26 - Sayı: 3, 192–201. https://ajindex.com/articles/512180

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol 2016
  2. S1-213. [Crossref] 2. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012
  3. [Crossref] 3. Prokopakis EP, Vlastos IM, Ferguson BJ, Scadding G, Kawauchi H, Georgalas C, et al. SCUAD and chronic rhinosinusitis. Reinforcing hypothesis driven research in difficult cases. Rhinology 2014
  4. [Crossref] 4. Smith KA, Orlandi RR, Rudmik L. Cost of adult chronic rhinosinusitis: A systematic review. Laryngoscope 2015
  5. [Crossref] 5. Günel C, Başak HS, Bleier BS. Oral steroids and intraoperative bleeding during endoscopic sinus surgery. B-ENT 2015
  6. Jund R, Mondigler M, Stammer H, Stierna P, Bachert C. Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis. Acta Otolaryngol 2015
  7. [Crossref] 7. Passali D, Cambi J, Passali FM, Bellussi LM. Phytoneering: a new way of therapy for rhinosinusitis. Acta Otorhinolaryngol Ital 2015
  8. Yaremchuk S, Zabolotny D, Vareniuk I, Makarchuk N, Veselsky S. Sinupret® oral drops protect against respiratory epithelium atrophy in experimental acute rhinitis. Clinical Phytoscience 2015
  9. [Crossref] 9. Popovich VI, Koshel IV. Sinupret® as add-on therapy to saline irrigation for children with acute post-viral rhinosinusitis. Clinical Phytoscience 2017
  10. [Crossref] 10. Richstein A, Mann W. Treatment of chronic rhinosinusitis with Sinupret. Schweiz Zschr Ganzheits Medizin 1999
  11. Palm J, Steiner I, Abramov-Sommariva D, Ammendola A, Mitzenheim S, Steindl H, et al. Assessment of efficacy and safety of the herbal medicinal product BNO 1016 in chronic rhinosinusitis. Rhinology 2017
  12. [Crossref] 12. Glatthaar-Saalmüller B, Rauchhaus U, Rode S, Haunschild J, Saalmüller A. Antiviral activity in vitro of two preperations of the herbal medicinal product Sinupret® against viruses causing respiratory infections. Phytomedicine 2011
  13. [Crossref] 13. Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology 1993
  14. Pfaar O, Mullol J, Anders C, Hörmann K, Klimek L. Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis: a randomized double-blind